Adobe
For all the explosive controversy over the approval of the first treatment for Alzheimer’s disease in nearly 20 years, hardly any patients have actually gotten it yet.
The drug’s eye-popping, $56,000 annual price and questionable benefit to patients have been a shock to the bureaucracy that makes the health care system run and that’s having a clear effect on uptake. Some analysts estimated last month that fewer than 100 patients were dosed in the first weeks after the therapy was approved, though availability will likely ramp up over the coming months.
Though the Food and Drug Administration said in approving the therapy, Aduhelm, that the data indicate a likely benefit, hospital and insurer committees are conducting their own analyses, acting as another set of gatekeepers. They regularly review new treatments, but the lingering questions about the drug’s efficacy, as well as the logistical challenges of delivering an infused drug, are complicating and prolonging t
E-Mail
IMAGE: Many traumatic brain injury (TBI) survivors needed extensive healthcare services in the year after their injury, and a quarter of them were super-utilizers, having three or more emergency department visits. view more
Credit: Regenstrief Institute
INDIANAPOLIS Patients who suffer from traumatic brain injuries (TBI) often need a great deal of healthcare services after the injury, but the extent of care utilization is unknown. A new study from research scientists affiliated with the U.S. Department of Veterans Affairs (VA), Regenstrief Institute and IUPUI is one of the first to analyze how much care TBI patients use and identify areas of unmet need.
Industry Veteran Andrea Heslin Smiley joins Rockwell Medical s Board of Directors marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.